Sir, The prevalence of serious infections (meningitis, pneumonia, respiratory tract infections) caused by strains of pneumococci with reduced susceptibility to penicillin is increasing throughout the world. 1 Thus, the third-generation cephalosporins cefotaxime and ceftriaxone have become important drugs in the treatment of pneumococcal infections, particularly in cases of meningitis. However, pneumococcal strains exhibiting high levels of resistance to these β-lactams have been described, 2-4 often associated with therapeutic failure. Furthermore, strains with diminished susceptibility to these two drugs have been observed in Portugal in the last few years. 5 The Antibiotic Resistance Unit of the National Institute of Health, Lisbon, collected 384 penicillin-resistant isolates of Streptococcus pneumoniae between January 1995 and December 2000 during a multicentre study involving 23 different laboratories; 105 of the isolates were invasive, from blood, cerebrospinal fluid or pleura, 250 were isolated from the respiratory tract and 29 were of unknown origin.
The MICs of penicillin (Wyeth Lederle Portugal-Farma, Algés, Portugal), cefotaxime (Hoechst Marion Roussel, Mem Martins, Portugal) and ceftriaxone (Roche Pharmaceuticals, Amadora, Portugal) were determined by the agar dilution method, according to NCCLS protocols. 6 Isolates were considered to be penicillin intermediate if the MIC of penicillin /L) , but the MIC 90 of cefotaxime for penicillin-resistant isolates was higher (2 mg/L) than that of ceftriaxone (1 mg/L). The MIC 50 s of the two cephalosporins were the same for invasive and non-invasive isolates (data not shown). However, ceftriaxone had a higher in vitro activity against invasive isolates (MIC 90 2 mg/L) than against non-invasive isolates (MIC 90 1 mg/L). The percentage of penicillin-resistant isolates with intermediate resistance to cefotaxime (65.8%) was lower than the percentage of penicillin-resistant isolates with intermediate resistance to ceftriaxone (83.6%). Conversely, more strains were resistant to cefotaxime (30.4%) than to ceftriaxone (10.1%).
Comparison of these results with those of a previous study demonstrates that the percentage of clinical isolates of S. pneumoniae with reduced susceptibility or resistance to third-generation cephalosporins has increased in Portugal. 5 The resistance of clinical isolates to cefotaxime and ceftriaxone is related to the decreased affinities of PBP 1a and PBP 2x, due to genetic recombination events and the accumulation of point mutations in the mosaic forms of the pbp genes. 2 Thus, we emphasize the importance of monitoring the susceptibility to these drugs in Portugal, especially in cases of pneumococcal meningitis, where resistance to β-lactams may result in treatment failure.
